Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2016

Open Access 01-12-2016 | Original investigation

Low and exacerbated levels of 1,5-anhydroglucitol are associated with cardiovascular events in patients after first-time elective percutaneous coronary intervention

Authors: Shuhei Takahashi, Kazunori Shimada, Katsumi Miyauchi, Tetsuro Miyazaki, Eiryu Sai, Manabu Ogita, Shuta Tsuboi, Hiroshi Tamura, Shinya Okazaki, Tomoyuki Shiozawa, Shohei Ouchi, Tatsuro Aikawa, Tomoyasu Kadoguchi, Hamad Al Shahi, Takuma Yoshihara, Makoto Hiki, Kikuo Isoda, Hiroyuki Daida

Published in: Cardiovascular Diabetology | Issue 1/2016

Login to get access

Abstract

Background

Postprandial hyperglycemia plays an important role in the pathogenesis of coronary artery disease and cardiovascular events. Serum 1,5-anhydroglucitol (1,5-AG) levels are known to be a clinical marker of postprandial hyperglycemia. However, the impact of 1,5-AG level on cardiovascular events has not been fully investigated.

Methods

We enrolled 240 consecutive patients who had undergone first-time elective percutaneous coronary intervention (PCI) with follow-up angiography within 1 year. We excluded patients with a history of acute coronary syndrome, advanced chronic kidney disease (estimated glomerular filtration rate <30 mL/min/1.73 m2), or uncontrolled diabetes mellitus (HbA1c ≥7.0%). Fasting blood glucose (FBS), HbA1c, and 1,5-AG levels were measured prior to PCI and at the time of follow-up angiography. Clinical events, including target lesion revascularization, target vessel revascularization, and revascularization of new lesions, were evaluated.

Results

Subjects were divided into two groups according to clinical outcomes: the Event (+) group (n = 40) and the Event (−) group (n = 200). No significant differences were observed, except for the number of diseased vessels and the prevalence of statin use, in baseline clinical characteristics between the two groups. Serum levels of 1,5-AG at follow-up were significantly lower in the Event (+) group than in the Event (−) group (P = 0.02). A significant reduction in 1,5-AG level from baseline to follow-up was observed in the Event (+) group compared with the Event (−) group (P = 0.04). The association between 1,5-AG levels at follow-up and clinical events remained significant after adjustment for independent variables, including FBS and HbA1c levels (P = 0.04).

Conclusions

Low and exacerbated levels of 1,5-AG were associated with cardiovascular events in the present study, indicating that postprandial hyperglycemia is an important risk factor for adverse clinical events even in patients with HbA1c < 7.0%, following first-time elective PCI.
Literature
1.
go back to reference Ceriello A, Hanefeld M, Leiter L, Monnier L, Moses A, Owens D. Postprandial glucose regulation and diabetic complications. Arch Intern Med. 2004;164:2090–5.CrossRefPubMed Ceriello A, Hanefeld M, Leiter L, Monnier L, Moses A, Owens D. Postprandial glucose regulation and diabetic complications. Arch Intern Med. 2004;164:2090–5.CrossRefPubMed
2.
go back to reference The DECODE study group on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria. Lancet. 1999;354:617–21.CrossRef The DECODE study group on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria. Lancet. 1999;354:617–21.CrossRef
3.
go back to reference Donahue RP, Abbott RD, Reed DM, Yano K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes. 1987;36:689–92.CrossRefPubMed Donahue RP, Abbott RD, Reed DM, Yano K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes. 1987;36:689–92.CrossRefPubMed
4.
go back to reference Fukao K, Shimada K, Hiki M, Kiyanagi T, Hirose K, Kume A, et al. Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between Azelnidipine and amlodipine on glucose tolerance and endothelial function—a crossover trial (AGENT). Cardiovasc Diabetol. 2011;10:79.CrossRefPubMedPubMedCentral Fukao K, Shimada K, Hiki M, Kiyanagi T, Hirose K, Kume A, et al. Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between Azelnidipine and amlodipine on glucose tolerance and endothelial function—a crossover trial (AGENT). Cardiovasc Diabetol. 2011;10:79.CrossRefPubMedPubMedCentral
5.
go back to reference Hiki M, Shimada K, Kiyanagi T, Fukao K, Hirose K, Ohsaka H, et al. Single Administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease-Juntendo University Trial: effects of Miglitol on Endothelial Vascular Reactivity in Type 2 Diabetic Patients With Coronary Heart Disease (J-MACH). Circ J. 2010;74:1471–8.CrossRefPubMed Hiki M, Shimada K, Kiyanagi T, Fukao K, Hirose K, Ohsaka H, et al. Single Administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease-Juntendo University Trial: effects of Miglitol on Endothelial Vascular Reactivity in Type 2 Diabetic Patients With Coronary Heart Disease (J-MACH). Circ J. 2010;74:1471–8.CrossRefPubMed
6.
go back to reference Dungan KM, Buse JB, Largay J, Kelly MM, Button EA, Kato S, et al. 1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care. 2006;29:1214–9.CrossRefPubMed Dungan KM, Buse JB, Largay J, Kelly MM, Button EA, Kato S, et al. 1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care. 2006;29:1214–9.CrossRefPubMed
7.
go back to reference Yamanouchi T, Ogata N, Tagaya T, Kawasaki T, Sekino N, Funato H, et al. Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control. Lancet. 1996;347:1514–8.CrossRefPubMed Yamanouchi T, Ogata N, Tagaya T, Kawasaki T, Sekino N, Funato H, et al. Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control. Lancet. 1996;347:1514–8.CrossRefPubMed
8.
go back to reference Torimoto K, Okada Y, Mori H, Tanaka Y. Low levels of 1,5-anhydro-d-glucitol are associated with vascular endothelial dysfunction in type 2 diabetes. Cardiovasc Diabetol. 2014;13:99.CrossRefPubMedPubMedCentral Torimoto K, Okada Y, Mori H, Tanaka Y. Low levels of 1,5-anhydro-d-glucitol are associated with vascular endothelial dysfunction in type 2 diabetes. Cardiovasc Diabetol. 2014;13:99.CrossRefPubMedPubMedCentral
9.
go back to reference Sato T, Kameyama T, Inoue H. Association of reduced levels of serum 1,5-anhydro-d-glucitol with carotid atherosclerosis in patients with type 2 diabetes. J Diabetes Complicat. 2014;28:348–52.CrossRefPubMed Sato T, Kameyama T, Inoue H. Association of reduced levels of serum 1,5-anhydro-d-glucitol with carotid atherosclerosis in patients with type 2 diabetes. J Diabetes Complicat. 2014;28:348–52.CrossRefPubMed
10.
go back to reference Ikeda N, Hara H, Hiroi Y. 1,5-Anhydro-D-glucitol predicts coronary artery disease prevalence and complexity. J Cardiol. 2014;64:297–301.CrossRefPubMed Ikeda N, Hara H, Hiroi Y. 1,5-Anhydro-D-glucitol predicts coronary artery disease prevalence and complexity. J Cardiol. 2014;64:297–301.CrossRefPubMed
11.
go back to reference Fujiwara T, Yoshida M, Yamada H, Tsukui T, Nakamura T, Sakakura K, et al. Lower 1,5-anhydroglucitol is associated with denovo coronary artery disease in patients at high cardiovascular risk. Heart Vessels. 2015;30:469–76.CrossRefPubMed Fujiwara T, Yoshida M, Yamada H, Tsukui T, Nakamura T, Sakakura K, et al. Lower 1,5-anhydroglucitol is associated with denovo coronary artery disease in patients at high cardiovascular risk. Heart Vessels. 2015;30:469–76.CrossRefPubMed
12.
go back to reference Watanabe M, Kokubo Y, Higashiyama A, Ono Y, Miyamoto Y, Okamura T. Serum 1,5-anhydro-d-glucitol levels predict first-ever cardiovascular disease: an 11-year population-based cohort study in Japan, the Suita study. Atherosclerosis. 2011;216:477–83.CrossRefPubMed Watanabe M, Kokubo Y, Higashiyama A, Ono Y, Miyamoto Y, Okamura T. Serum 1,5-anhydro-d-glucitol levels predict first-ever cardiovascular disease: an 11-year population-based cohort study in Japan, the Suita study. Atherosclerosis. 2011;216:477–83.CrossRefPubMed
13.
go back to reference Selvin E, Rawlings A, Lutsey P, Maruthur N, Pankow JS, Steffes M, et al. Association of 1,5-anhydroglucitol with cardiovascular disease and mortality. Diabetes. 2016;65:201–8.PubMed Selvin E, Rawlings A, Lutsey P, Maruthur N, Pankow JS, Steffes M, et al. Association of 1,5-anhydroglucitol with cardiovascular disease and mortality. Diabetes. 2016;65:201–8.PubMed
14.
go back to reference Fujiwara T, Yoshida M, Akashi N, Yamada H, Tsukui T, Nakamura T, et al. Lower 1,5-anhydroglucitol is associated with adverse clinical events after percutaneous coronary intervention. Heart Vessels. 2016;31:855–62.CrossRefPubMed Fujiwara T, Yoshida M, Akashi N, Yamada H, Tsukui T, Nakamura T, et al. Lower 1,5-anhydroglucitol is associated with adverse clinical events after percutaneous coronary intervention. Heart Vessels. 2016;31:855–62.CrossRefPubMed
15.
go back to reference American Diabetes Association. 5. Glycemic targets. Diabetes Care. 2016;39:S39–46.CrossRef American Diabetes Association. 5. Glycemic targets. Diabetes Care. 2016;39:S39–46.CrossRef
16.
go back to reference Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58:429–42.CrossRefPubMed Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58:429–42.CrossRefPubMed
17.
go back to reference Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRefPubMed Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRefPubMed
18.
go back to reference Ogita M, Miyauchi K, Jiang M, Kasai T, Tsuboi S, Naito R, et al. Circulating soluble LR11, a novel marker of smooth muscle cell proliferation, is enhanced after coronary stenting in response to vascular injury. Atherosclerosis. 2014;237:374–8.CrossRefPubMed Ogita M, Miyauchi K, Jiang M, Kasai T, Tsuboi S, Naito R, et al. Circulating soluble LR11, a novel marker of smooth muscle cell proliferation, is enhanced after coronary stenting in response to vascular injury. Atherosclerosis. 2014;237:374–8.CrossRefPubMed
19.
go back to reference Miyazaki T, Shimada K, Miyauchi K, Kume A, Tanimoto K, Kiyanagi T, et al. Effects of fenofibrate on lipid profiles, cholesterol ester transfer activity, and in-stent intimal hyperplasia in patients after elective coronary stenting. Lipids Health Dis. 2010;9:122.CrossRefPubMedPubMedCentral Miyazaki T, Shimada K, Miyauchi K, Kume A, Tanimoto K, Kiyanagi T, et al. Effects of fenofibrate on lipid profiles, cholesterol ester transfer activity, and in-stent intimal hyperplasia in patients after elective coronary stenting. Lipids Health Dis. 2010;9:122.CrossRefPubMedPubMedCentral
20.
go back to reference Cassese S, Byrne RA, Tada T, Pinieck S, Joner M, Ibrahim T, et al. Incidence and predictors of restenosis after coronary stenting in 10,004 patients with surveillance angiography. Heart. 2014;100:153–9.CrossRefPubMed Cassese S, Byrne RA, Tada T, Pinieck S, Joner M, Ibrahim T, et al. Incidence and predictors of restenosis after coronary stenting in 10,004 patients with surveillance angiography. Heart. 2014;100:153–9.CrossRefPubMed
21.
go back to reference Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.CrossRefPubMed Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.CrossRefPubMed
22.
go back to reference Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.CrossRefPubMed Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.CrossRefPubMed
23.
go back to reference Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–39.CrossRefPubMed Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–39.CrossRefPubMed
24.
go back to reference Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 1999;22:920–4.CrossRefPubMed Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 1999;22:920–4.CrossRefPubMed
25.
go back to reference Miyazaki T, Shimada K, Iwama Y, Kume A, Sumiyoshi K, Sato Y, et al. Insulin response to oral glucose load is associated with coronary artery disease in subjects with normal glucose tolerance. J Atheroscler Thromb. 2008;15:6–12.CrossRefPubMed Miyazaki T, Shimada K, Iwama Y, Kume A, Sumiyoshi K, Sato Y, et al. Insulin response to oral glucose load is associated with coronary artery disease in subjects with normal glucose tolerance. J Atheroscler Thromb. 2008;15:6–12.CrossRefPubMed
26.
go back to reference Liang M, McEvoy JW, Chen Y, Sharrett AR, Selvin E. Association of 1,5-anhydroglucitol, a biomarker of glucose peaks, with subclinical cardiovascular disease. Diabetes Care. 2016. doi:10.2337/dc16-0840 (Epub ahead of print). Liang M, McEvoy JW, Chen Y, Sharrett AR, Selvin E. Association of 1,5-anhydroglucitol, a biomarker of glucose peaks, with subclinical cardiovascular disease. Diabetes Care. 2016. doi:10.​2337/​dc16-0840 (Epub ahead of print).
27.
go back to reference Kim MK, Jung HS, Kwak SH, Cho YM, Park KS, Kim SY. 1,5-Anhydro-d-glucitol could reflect hypoglycemia risk in patients with type 2 diabetes receiving insulin therapy. Endocrinol Metab. 2016;31:284–91.CrossRef Kim MK, Jung HS, Kwak SH, Cho YM, Park KS, Kim SY. 1,5-Anhydro-d-glucitol could reflect hypoglycemia risk in patients with type 2 diabetes receiving insulin therapy. Endocrinol Metab. 2016;31:284–91.CrossRef
28.
go back to reference Ma X, Hu X, Zhou J, Hao Y, Luo Y, Lu Z, et al. Glycated albumin is more closely correlated with coronary artery disease than 1,5-anhydroglucitol and glycated hemoglobin A1c. Cardiovasc Diabetol. 2015;14:16.CrossRefPubMedPubMedCentral Ma X, Hu X, Zhou J, Hao Y, Luo Y, Lu Z, et al. Glycated albumin is more closely correlated with coronary artery disease than 1,5-anhydroglucitol and glycated hemoglobin A1c. Cardiovasc Diabetol. 2015;14:16.CrossRefPubMedPubMedCentral
29.
go back to reference Mukai N, Ninomiya T, Hata J, Hirakawa Y, Ikeda F, Fukuhara M, et al. Association of hemoglobin A1c and glycated albumin with carotid atherosclerosis in community-dwelling Japanese subjects: the Hisayama study. Cardiovasc Diabetol. 2015;14:84.CrossRefPubMedPubMedCentral Mukai N, Ninomiya T, Hata J, Hirakawa Y, Ikeda F, Fukuhara M, et al. Association of hemoglobin A1c and glycated albumin with carotid atherosclerosis in community-dwelling Japanese subjects: the Hisayama study. Cardiovasc Diabetol. 2015;14:84.CrossRefPubMedPubMedCentral
Metadata
Title
Low and exacerbated levels of 1,5-anhydroglucitol are associated with cardiovascular events in patients after first-time elective percutaneous coronary intervention
Authors
Shuhei Takahashi
Kazunori Shimada
Katsumi Miyauchi
Tetsuro Miyazaki
Eiryu Sai
Manabu Ogita
Shuta Tsuboi
Hiroshi Tamura
Shinya Okazaki
Tomoyuki Shiozawa
Shohei Ouchi
Tatsuro Aikawa
Tomoyasu Kadoguchi
Hamad Al Shahi
Takuma Yoshihara
Makoto Hiki
Kikuo Isoda
Hiroyuki Daida
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2016
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-016-0459-5

Other articles of this Issue 1/2016

Cardiovascular Diabetology 1/2016 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.